INTRODUCTION
• Psoriasis has profound psychosocial implications that can affect the ability of patients to socialize with family members, interact with coworkers, and make friends 1 • Psychiatric comorbidities, such as depression and anxiety, are common in patients with psoriasis 2,3 • Suicidal ideation has been reported in as many as 17.3% of patients with psoriasis compared with 8.3% of healthy controls 4 • Brodalumab is a monoclonal antibody that targets interleukin-17 receptor A and is indicated for the treatment of psoriasis 5 • Brodalumab has demonstrated efficacy in the treatment of plaque psoriasis 5, 6 • Reports of suicide in patients with psoriasis enrolled in clinical trials for brodalumab led to concerns that brodalumab may be linked to psychiatric adverse events (AEs) 6, 7 
OBJECTIVE
• To assess psychiatric AEs and improvements in depression and anxiety in patients with psoriasis treated with brodalumab in clinical trials
METHODS

Clinical studies
• Efficacy and safety of brodalumab (140 or 210 mg every 2 weeks [Q2W]) were investigated in one phase 2 trial and in three phase 3, multicenter, randomized trials of patients with moderate-to-severe plaque psoriasis (AMAGINE-1/-2/-3) 5,6 • In the phase 3 studies, more than 80% of patients were being treated with brodalumab 210 mg Q2W by the end of the week 52 controlled period • There were no specific exclusion criteria for psychiatric disorders or substance abuse
Endpoints
• The hospital anxiety and depression scale (HADS), which determines anxiety and depression on a 21-point scale each, was measured in AMAGINE-1 • The dermatology life quality index (DLQI) assesses the socio-psychological impact of the skin disease 8 on patients' lives and was measured in AMAGINE-1/-2/-3 • Data on psychiatric AEs were pooled for all trials and were summarized as follow-up time-adjusted event rates
-The follow-up time-adjusted event rate is the total number of events reported during the follow-up observation time divided by total patient-years of observation; this includes gaps and interruptions in exposure and time beyond the exposure period
RESULTS
• Mean HADS anxiety and depression scores significantly improved with brodalumab compared with placebo by 12 weeks (Figure 1) • Mean DLQI significantly improved with brodalumab compared with placebo by 12 weeks (Figure 2) • Rates of psychiatric adverse events were comparable between treatments at week 52 and did not increase with long-term treatment (Table 1) • There were 22 suicidal ideations (follow-up time-adjusted rate, 0.24), 6 suicide attempts (0.07), 3 completed suicides (0.03), and 1 additional suicide adjudicated as indeterminate (Table 2) • Two suicidal ideation and behavior (SIB) events (suicide attempts) were reported in 1 patient treated with brodalumab during the 12-week induction phase (0.03%; 1/3066) • Follow-up time-adjusted rates of SIB were greater in patients with a history of depression compared with those without (1.42 and 0.21 per 100 patient-years, respectively) • Follow-up time-adjusted rates of SIB were greater in patients with a history of suicidality compared with those without (3.21 and 0.20 per 100 patient-years, respectively)
• Of the 3 completed suicides, all patients were receiving brodalumab 210 mg, had baseline risk factors, and had demonstrated clinical responses (PASI ≥73; SOC, system organ class. a Includes data from the placebo-controlled phase 2 study, AMAGINE-1, AMAGINE-2, and AMAGINE-3. b All brodalumab dose groups combined. 
